Company profile
Gelesis Holdings, Inc.
OTC: GLSHQ · Healthcare · Biotechnology
#525 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ 12GM —SS 35
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), workforce scale · ↓ disclosure history, market scale
Methodology →Revenue TTM
$12.1M
Rev growth YoY (TTM)
-45.8%
Net income (FY)
-$55.8M
Employees
93
as of 2026-08-30
Market cap
$7.3k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$25.8M$25.8M2022
Net income-$55.8M-$55.8M2022
Operating income-$121.8M-$121.8M2022
Total assets$103.3M$103.3M2022
Liabilities$115.8M$115.8M2022
Equity-$25.1M-$25.1M2022
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Gelesis Holdings, Inc.’s revenue?
Gelesis Holdings, Inc. booked $25.8M in FY2022 revenue, growing 130% year over year — faster than most Healthcare companies we track, at a -216.5% net margin.
Peers · Healthcare
Synovics Pharmaceuticals, Inc.——Biocept, Inc.——RBC Life Sciences, Inc.——Avant Brands Inc.59CEntrada Therapeutics, Inc.46DMetagenomi, Inc. Common Stock40DNeighbors
Suffolk →Key facts
CEOAlessandro Sannino
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeOTC: GLSHQ
Employees93
IPO date2020-08-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.